SCHEMBL6286691

SCHEMBL6286691

CC(=O)O[C@@H](C)CCCCn1c(=O)c2c(=O)cc(C)n(Cc3ccccc3)c2n(C)c1=O

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.37
SMN1; SMN2 Q16637 5/20 0.36
MAPK1 P28482 1/20 0.36
TSHR P16473 2/20 0.36
ALDH1A1 P00352 4/20 0.36
LMNA P02545 4/20 0.36
KDM4E B2RXH2 2/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.35
HPD P32754 1/20 0.35
TRPC5 Q9UL62 1/20 0.35
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6287628 1.00 NOTUM (0.37) NOTUMSMN1; SMN2MAPK1TSHRALDH1A1
SCHEMBL6286693 1.00 NOTUM (0.37) NOTUMSMN1; SMN2MAPK1TSHRALDH1A1
SCHEMBL6289970 0.87 MAPK1 (0.36) SMN1; SMN2MAPK1ALDH1A1LMNAKMT2A
SCHEMBL6289968 0.87 MAPK1 (0.36) SMN1; SMN2MAPK1ALDH1A1LMNAKMT2A
SCHEMBL6289981 0.87 SMN1; SMN2 (0.40) NOTUMSMN1; SMN2MAPK1ALDH1A1LMNA
SCHEMBL6286338 0.87 SMN1; SMN2 (0.40) NOTUMSMN1; SMN2MAPK1ALDH1A1LMNA
SCHEMBL6286332 0.87 SMN1; SMN2 (0.40) NOTUMSMN1; SMN2MAPK1ALDH1A1LMNA
SCHEMBL6289523 0.85 SMN1; SMN2 (0.40) NOTUMSMN1; SMN2MAPK1TSHRALDH1A1
SCHEMBL6289522 0.85 SMN1; SMN2 (0.40) NOTUMSMN1; SMN2MAPK1TSHRALDH1A1
SCHEMBL6286795 0.83 SMN1; SMN2 (0.39) NOTUMSMN1; SMN2MAPK1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059685-A1 Pyridopyrimidine compounds and their uses CELL THERAPEUTICS, INC. (US) 2005-03-17 US disclosed
US-6825180-B2 CYTOKINE INTRACELLULAR SIGNALING INHIBITORS; ANTIINFLAMMATORY AGENTS CELL THERAPEUTICS, INC. 2004-11-30 US disclosed
US-20040023995-A1 Pyridopyrimidine compounds and their uses CELL THERAPEUTICS, INC. 2004-02-05 US disclosed
WO-2002094824-A1 PYRIDOPYRIMIDINE COMPOUNDS AND THEIR USES CELL THERAPEUTICS, INC. (US) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023995-A1 Pyridopyrimidine compounds and their uses PLPBP, MAVS, PDXK NOTUM 4722/4885SMN1; SMN2 1228/4885MAPK1 97/4885
US-20050059685-A1 Pyridopyrimidine compounds and their uses PLPBP, MAVS, PDXK NOTUM 4722/4885SMN1; SMN2 1228/4885MAPK1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.